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Rationale for using insensitive quality control rules for
today’s hematology analyzers
G .S .C E M B R O W S K I ,B .S M I T H ,D .T U N G
INTRODUCTION
Diverse approaches have been used to assure the ana-
lytical quality of automated hematology analyzers.
These approaches encompass the re-analysis of
retained patient specimens (Cembrowski et al., 1988;
Hackney & Cembrowski, 1990) averaging selected
consecutive patient measurements including red blood
cell indices (patient moving averages) (Bull et al.,
1974; Koepke & Protextor, 1981; Levy, Hay & Bull,
1986); as well as the use of stabilized hematology con-
trol products. Each of these procedures has certain
advantages and disadvantages in terms of practicality
and error detection capabilities. While the re-analysis
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SUMMARY
Diverse approaches have been used to assure the analytical quality of
automated hematology; as such, there is great variation in their error
detection capabilities. We summarize the intralaboratory performance
of a cohort of Sysmex XE-2100’s running e-Check hematology quality
control (QC). The imprecisions of a median performing (50th percentile
imprecision) and more imprecise [15th percentile (15P) imprecision]
Sysmex XE-2100 are compared with measures of total allowable error
(regulatory and physiologically based) to obtain multiples of the usual
imprecision that must be detected to prevent the hematology analyzer
from producing medically unacceptable results. The resultant large
multiples of the usual imprecision (s) demonstrate the need for
insensitive QC rules employing very broad control ranges, control rules
that have been implicitly supported by hematology analyzer manu-
facturers for the last several decades. For today’s highly precise
hematology analyzers, the following control rules are strongly advised:
13.5s,1 4s and 14.5s rules (violated if a single control observation exceeds
either its ±3.5, ±4.0 and ±4.5s limits, respectively). In order for the
hematology laboratory to totally embrace expanded QC limits, man-
ufacturers must make available their instruments’ usual and poorer
(e.g. the 15P performance) imprecision’s. Users of hematology analyz-
ers that require more sensitive but less speciﬁc rules to prevent the
reporting of clinically erroneous data are advised to acquire more
precise (and thus more dependable) instrumentation.
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generally used to detect short-term (within day)
trends and shifts. Averages of patient data are
susceptible to changes in the population of patients
being analyzed (Cembrowski & Westgard, 1985); the
ambient room temperature and even the temperature
of the hematology reagents (Cembrowski, Hodgson &
Etches, 2002). Commercial quality control (QC)
materials are often regarded as expensive, variably
sensitive in the detection of analytical errors and
subject to artifactual error because of constituent
instability.
The error detection capabilities of these procedures
differ greatly and are best described by power function
curves, which are plots of error detection vs. the size
of error. Westgard has provided power function curves
for control rules based on the analysis of reference
sample materials (commercial QC material) (Westgard
& Groth, 1979). Cembrowski and others have devel-
oped power function plots for QC procedures using
retained patient specimens and moving averages of
patient data (Cembrowski et al., 1988; Cembrowski &
Westgard, 1985; Lunetzky & Cembrowski, 1987).
These power function curves show that reference
sample QC procedures will detect analytical error
more quickly and more accurately than either
retained patient samples or moving averages
(Westgard & Cembrowski, 1990).
While virtually all laboratories in developed coun-
tries analyze commercial control materials for hematol-
ogy QC, there is signiﬁcant variation in the setup and
interpretation of the hematology QC. The control limits
are variable with some laboratories using the limits
supplied by the manufacturer, and others using control
limits that are derived statistically from preliminary
analysis of the new QC material. The frequency of con-
trol material analysis varies. Some laboratories analyze
controls every 8 or 12 h. Other laboratories ‘bracket’
groups of patient specimens with QC specimens or
retained, previously analyzed specimens. There is also
signiﬁcant variation in the control rules and control
procedures (combinations of QC rules applied in a
deﬁned manner) used to interpret the QC data. Table 1
shows some popular QC rules.
A 1994 College of American Pathologists Q-Probe
surveyed the QC practices in 505 primarily US health
care institutions (39% teaching and 61% nonteach-
ing) (Howanitz, Tetrault & Steindel, 1997). Overall,
Table 1. Examples of quality control rules (s, standard deviation)
Rule Deﬁnition Comments
12s Use as a rejection or warning when one control observation
exceeds the x ±2 s control limits; usually used as a warning
Overused. Should only be used with
manual assays with low number of
analytes/control materials
13s Reject a run when one control observation exceeds the x ±3 s
control limits
Detects increased imprecision
(random error) and shifts (systematic
error)
13.5s Reject a run when one control observation exceeds the
x ± 3.5s control limits
Detects increased imprecision
(random error) and shifts (systematic
error)
14s Reject a run when one control observation exceeds the x ±4 s
control limits
14.5s Reject a run when one control observation exceeds the
x ± 4.5s control limits
22s Reject a run when two consecutive control observations are
on the same side of the mean and exceed the x +2 s or x ) 2s
control limits
Detects shifts (systematic error), may
be applied across analytic runs
(within control materials) and
within analytic runs (across control
materials)
2/32s Reject a run when two of three control observations are on
the same side of the mean and exceed the x +2 s or x ) 2s
control limits
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seven were QC specimens. 0.36% of runs were
rejected and resulted in 0.3% of patient specimens
being rerun and 25-minute investigational delays for
each rejected run. For every 100 specimens measured,
only 91 analyses were billable. On average, 40% of
participants applied more than one QC rule; all told,
15 different QC rules were used to detect analytical
errors in hemoglobin (Hgb). While participants tended
to use QC rules that detected shifts or biases, these
types of errors were in the minority and caused QC
exceptions only 16% of the time. The survey indi-
cated a lack of adherence to QC policy. While 31% of
the laboratories had a policy to repeat all rejected
patient samples, only 4% adhered to this policy.
Sadly, 51% of participants excluded rejected control
values from statistical analysis and 66% of participants
re-measured the same control sample when an excep-
tion occurred rather than measuring a new specimen.
The study authors concluded that ‘laboratorians have
difﬁculty in following QC rules because they are com-
plex, tedious to follow, and in some cases impractical’.
It is incongruous that the quality of today’s multi-
channel hematology analyzers is generally undisputed,
yet the practice of hematology QC is heterogeneous
and seemingly arbitrary. It may be that these analyzers
are robust and usually produce clinically acceptable
data and that many of today’s QC procedures are non-
speciﬁc and lead to nonproductive practices. In this
study, we evaluate the stability of e-Check hematology
QC product as analyzed by a cohort of laboratories
using a representative robust hematology analyzer, the
Sysmex XE-2100 (Johnson et al., 2002). We summa-
rize the intralaboratory performance of this cohort of
Sysmex XE-2100’s. The imprecision of a median per-
forming analyzer (50th percentile imprecision) and a
less than average analyzer [15th percentile (15P)
imprecision] are compared with estimates of maxi-
mum allowable error (MAE). The MAE corresponds to
the largest amount of error that can be added to a
test result before the test result becomes unﬁt for med-
ical use. While the MAE should be considered a total
error and includes pre-analytic and analytic error, lab-
oratorians usually focus on analytic error. Many
American laboratorians interchange MAE and the US
Clinical Laboratory Improvement Amendments (CLIA;
Medicare Medicaid and CLIA programs, 1992) limits
for proﬁciency testing. As the CLIA error limits are
extremely broad, somewhat subjective, and not
deﬁned for many analytes, physiologically based esti-
mates of MAE (Ricos et al., 1999) have been embraced
by the laboratory community.
The ratio of MAE to the analytical imprecision
(CVa) (MAE:CVa) dictates the QC rule that should be
used to detect analytically important error. A high
ratio (exceeding 4–5) indicates a very tightly con-
trolled analytical process. For such high ratios, QC
rules such as the 13.5s,1 4s and 14.5s are adequate. For
MAE:CVa values of 3–4, tighter control limits are
required to detect analytically signiﬁcant error. A con-
trol procedure combining the 13s and the 22s control
rules will generally sufﬁce for these intermediate ratio
tests.
MATERIALS AND METHODS
The Sysmex XE-2100 is an automated discrete hema-
tology analyzer designed for high-volume clinical labo-
ratory testing (maximum throughput of 150 samples/
h). It provides a 14-parameter hemogram, a 5-part
leukocyte differential, reticulocyte analysis including
immature reticulocyte fraction, and a nucleated red
blood cell (NRBC) count. Differential parameters, retic-
ulocyte analysis, and NRBC counts are determined
using ﬂow cytometry, a semi-conductor laser and ﬂuo-
rescent dyes (Walters & Garrity, 2003). The Sysmex
XE-2100 also measures and charts 16 other detector
control parameters. Samples may either be run in the
automated aspiration (closed) sampling mode using a
sample volume of 200 ll or in the manual (open) sam-
pling mode using a 130 ll sample volume.
The Sysmex XE-2100 uses a three level control
product, Sysmex e-Check, for process QC. This mate-
rial consists of a stabilized whole blood mixture of
human erythrocytes, human and simulated leukocytes
and platelets (PLT). If promptly refrigerated after each
use, the material has a 73-day closed vial stability and
a 7-day open vial stability. Table 2 shows the target
means for the three levels of control material. The QC
materials’ basophil counts are so elevated that they
are not incorporated into the total white blood cell
(WBC) count.
The QC data are transmitted regularly from the
Sysmex XE-2100 to the Sysmex Insight Program.
This program provides calculations of the individual
laboratory’s mean and SD for each control and
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tics. These calculations are continuously available via
the World Wide Web. Group summary reports are
also produced at the end of each 30-day period. We
obtained two 30-day summaries of submitted data for
Sysmex e-Check lot number 2197 from 121 different
laboratories in PDF format (Adobe Software, San Jose,
CA, USA) for the periods of July 17, 2002 to August
15, 2002 (period 1) and August 16, 2002 to Septem-
ber 20, 2002 (period 2). These summaries were con-
verted into text ﬁles and the text data extracted into
Microsoft Access, Crystal Reports and Microsoft Excel
to provide data summaries and graphs.
We tabulated the individual Sysmex Insight intra-
laboratory CV for each analyte and determined the
following CV: 10P, 15P, 50P, 85P and the 90P, 95P
and the 99P with the highest percentiles correspond-
ing to the most precise performance. Graphs were
constructed showing the 10–99P CV for the analytes
shown in Table 2. Periods 1 and 2 were plotted
separately to more easily evaluate control product
stability.
Two types of MAE estimates were used. In addition
to the U.S. CLIA proﬁciency testing limits (Medicare
Medicaid and CLIA programs, 1992), we also used
two set of allowable errors based on physiological
variation (Ricos et al., 1999). One set encompassed
95% of observations and the other, 99%. We calcu-
lated the MAE:CVa ratios for both the 15P and 50P
CV. We also calculated the error magnitude (mea-
sured in number of SD’s) required in the results
before an error would exceed the manufacturer’s
limits. Finally, the differences between the MAE:CVa
ratios and the QC error magnitudes were calculated
(Figure 5).
RESULTS
The participants consisted of hospital and nonhospital
laboratories. Most laboratories ran all three levels of
control material. In period 1, reports were available
for 115 analyzers from 88 laboratories, 24 of which
used multiple analyzers. Six analyzers ran the QC
both in the ‘closed’ and ‘open’ sampling mode, for a
total of 121 sets of data. About 110 sets of data were
obtained in the ‘closed’ mode and the remainder was
run ‘open’. Three laboratories (six analyzers) did not
provide period 2 control data. On average, 60 controls
were analyzed at each control level.
In period 2, reports were available for 153 analyz-
ers from 118 laboratories; 32 of which used multiple
analyzers. Nine analyzers ran QC both in the ‘closed’
and ‘open’ sampling mode, for a total of 162 sets of
data. One hundred and forty nine sets of data were
obtained in the ‘closed’ mode and the remainder was
run ‘open’.
On average, 70 controls were analyzed at each
control level. In a sample of 50 hospital laboratories
that maintained 24-h services, 46% ran QC three
times per day, 34% ran two times per day, 14% four
times a day and 6% ran QC only once a day.
Table 2. Package Insert Targets for Sysmex e-Check lot
no. 2197
Mean concentrations
Level 1 Level 2 Level 3
Baso#, 10
9/l 1.4 4.2 12.2
Baso% 58.7 62.8 69.5
Eo#, 10
9/l 0.2 0.6 1.8
Eo% 7.6 9.2 10.2
Hct, % 17.6 36.7 47.0
Hgb, g/dl 6.0 12.8 16.8
IRF, % 28.8 27.6 25.1
Lymph#, 10
9/l 1.1 2.5 5.3
Lymph% 44.2 36.9 30.4
MCH, pg 25.8 29.3 32.7
MCHC, g/dl 34.0 35.0 35.7
MCV, ﬂ 75.9 83.9 91.4
Mono#, 10
9/l 0.3 0.7 2.2
Mono% 14.0 11.1 12.3
MPV, ﬂ 9.5 9.7 9.8
Neut#, 10
9/l 0.8 2.8 8.3
Neut% 34.3 42.7 47.2
PLT, 10
9/l 53.0 206.0 464.0
PLT-O, 10
9/l 61.0 201.0 458.0
RBC, 10
12/l 2.33 4.37 5.14
RDW-SD, ﬂ 42.4 41.8 46.7
Ret#, 10
12/l 0.2 0.1 0.1
Ret% 7.4 3.3 1.1
WBC, 10
9/l 2.4 6.6 17.5
% indicates the percentage of WBC (white blood cells)
represented by the white cell moiety in question, e.g.
Baso% is the percentage of WBC represented by basoph-
ils; #, the absolute count of the white cell moiety, e.g.
Baso# represents the absolute number of basophils/l;
PLT-O, optical platelet count; RBC, red blood cell; IRF,
immature reticulocyte fraction.
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1 and period 2 imprecisions for leukocytes/PLT, red
blood cell parameters, leukocyte differential parame-
ters and reticulocyte parameters, respectively. The
period 1 and period 2 imprecisions were not statisti-
cally different for all tests except for MCV (P < 0.01).
Figure 1. (a–d) Comparison of period 1 and 2 CV for 10, 15, 50, 85, 90, 95 and 99 percentile Sysmex XE-2100
instruments for leukocytes/platelets (a), red blood cell parameters (b), leukocyte differential parameters (c) and
reticulocyte parameters (d).
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have an MAE:CVa ratio >4 except for mean corpuscu-
lar hemoglobin (MCH), mean corpuscular hemoglobin
concentration (MCHC) and mean corpuscular volume
(MCV). Figure 4 displays the shift from the mean
(measured in number of SD’s) required in QC samples
for the manufacturer QC limits to be violated (15P
and 50P; level 2). For example, a Hgb result for a level
2 QC sample run on a 50P analyzer that is 4 SD out-
side the expected mean will result in an error.
Figure 5 shows the difference between the MAE
and the manufacturer’s QC limits (expressed in multi-
ples of SD) for the 15P analyzers running level 2 QC
samples. Negative differences indicate that the QC
limits are wider than the MAE limits and that any out
of QC limits value will also violate the MAE limits.
More importantly, in these cases some errors may
exceed MAE limits without causing QC violations,
leading to unsuspected reporting of erroneous results.
The positive differences indicate that QC limits are
narrower than MAE limits. In this scenario, it is not
possible to exceed the MAE limits without also violat-
ing the QC limits, therefore all signiﬁcant errors
should be detectable and potentially correctable.
DISCUSSION
Imprecision
The period 1 and period 2 CV are somewhat larger
than those demonstrated in an early XE-2100 evalua-
tion (Walters & Garrity, 2003). Published evaluations
of multichannel hematology instruments are generally
performed by few individuals on a single analyzer over
a 20-day period using a limited number of samples.
Our work represents multiple analyzers run over
60-day periods and reﬂects variation in multiple
instruments, reagent lot numbers and operators.
Figure 1 shows that the period 1 and 2 CV’s are almost
superimposable. While the CV of MCV increased by
Figure 2. Maximum allowable error:CVa ratios for 15th percentile CV analyzers.
[Correction added on 22 September 2010, after ﬁrst online publication: The wrong data for Figure 2 was used
during typesetting and this has been corrected.]
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2–50P) reﬂecting a very small analytical and even a
smaller clinical change. The Sysmex XE-2100 directly
measures hematocrit (Hct), RBC and Hgb, while MCH,
MCHC and MCV are calculated using the aforemen-
tioned measured values. Therefore the imprecisions of
MCH, MCHC and MCV reﬂects the collective impreci-
sions of the Hct, RBC and Hgb measurements.
Ratio of allowable error to imprecision and quality
control limits
When using the CLIA limits, the MAE:CVa ratios
exceed 5 for all analytes for the 15P (below average)
analyzers (Figure 2). When the samples are run on a
50P (average) analyzer, the ratios exceed 6 (Figure 3).
When using the physiologic variation limits, the
MAE:CVa ratios of most of the analytes exceed 4 for
15P and 50P instruments. While the MCV and Hct
ratios cluster around 4, the MCH and MCHC ratios
are closer to 2. Most of the QC limits used by the
manufacturer appear to approximate the 3.5, 4 and
4.5s control limits (Figure 4). However, for absolute
lymphocyte counts, MCH and MCV the control limits
range from 4.5 to 8s. The control limits are in excess
of 10s for red cell distribution width (RDW) and abso-
lute basophil/monocyte counts.
Maximum allowable error quality control limits
Using the CLIA limits, the manufacturer QC limits are
narrower than the MAE for the 15P analyzer
(Figure 5) as well as the 50P analyzer. Therefore, the
relatively insensitive manufacturer QC limits can
detect errors in hematocrit, Hgb, PLT, RBC and WBC
before a CLIA limit is violated. The QC limits can
detect errors before the P < 0.05 physiologic limit is
exceeded for leukocyte, neutrophil, eosinophil and
basophil counts, Hgb, PLT and RBC. With the use of
P < 0.01 physiologic limits, this list of analytes would
also include mean platelet volume (MPV) and Hct. Of
these tests, Hgb, PLT, leukocyte count and neutrophil
number, are probably the most clinically useful and
most commonly ordered tests. With reference to those
Figure 3. Maximum allowable error:CVa ratios for 50th percentile CV analyzers.
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than the QC limits, three of the tests, MCV, MCH and
MCHC are calculated by the Sysmex. We have found
that the investigation of deviations in calculated
parameters is not productive as these deviations usu-
ally arise from simultaneous errors in two or more of
the constituent measurements.
The QC limits for Hct and MPV appear to approxi-
mate the physiologic limits. Unlike Hgb, clinicians
generally do not follow Hct serially; however, values
outside the reference range elicit attention. Generally,
values <0.3 are considered to be clinically signiﬁcant,
which is well below the lower limit of the normal ref-
erence range (0.36 and 0.41 for women and men,
respectively). Therefore, deviations well in excess of
the QC limits (±0.014) are required before clinical
intervention is required. For MPV, an uncommonly
ordered and rarely reported parameter, the clinically
signiﬁcant changes appear to be at least twice as much
as the physiologic limits (Khandekar et al., 2006).
Therefore, the QC limits for MPV still have the poten-
tial to detect errors before they become clinically rele-
vant. RDW-SD is another parameter that typically
prompts further investigation only if it is outside the
normal reference range (37–50 ﬂ). Of note, RDW-SD
is rarely studied in isolation, but rather in combina-
tion with other CBC parameters and cell morphology.
RDW-SD also has only limited clinical utility; it is gen-
erally increased in iron deﬁciency anemia and some
hemoglobinopathies and usually normal in thalasse-
mia. For these diseases other CBC parameters serve as
more reliable markers. Therefore, the broad QC limits
for RDW-SD (±3.68 ﬂ) are unlikely to lead to any
clinically signiﬁcant errors. The QC limit for lympho-
cyte number (±0.3 · 10
9) is similar to the physiologic
limit while the QC limits for monocyte number
(±0.4 · 10
9) are wider. The tight lymphocyte QC lim-
its are adequate for lymphocytosis, where lymphocyte
numbers are generally increased well in excess of the
QC limits. Unfortunately, the QC limits may be too
wide for lymphopenia, monocytopenia and monocyto-
sis. For example, a monocyte count >1 · 10
9/l is con-
Figure 4. Shift required (in number of SD) before error is signaled by quality control (QC) result being out of manu-
facturer QC limits (level 2 control product).
  2010 Blackwell Publishing Ltd, Int. Jnl. Lab. Hem. 2010, 32, 606–615
G .S .C E M B R O W S K I ,B .S M I T HA N DD .T U N G EXPANDED QUALITY CONTROL LIMITS FOR HEMATOLOGY 613sidered clinically signiﬁcant, therefore, the possibility
exists that a negative shift in the results will provide a
false negative without violating the QC limits. Mono-
cytes may be elevated in chronic infections and myelo-
proliferative/myelodysplastic disorders. However, we
have other markers such as neutrophil and leukocyte
number for infectious processes. Patients with myelo-
proliferative disorders do not typically present with
isolated monocytosis but also demonstrate other cyto-
sis, distinctive cytologic and histologic features, pheno-
typic changes on ﬂow cytometry and abnormal clinical
ﬁndings. Therefore, the possibility of clinical signiﬁcant
error appears to be remote.
It is our belief, based on the information in
Figures 2, 3 and 5 that the QC limits recommended by
the manufacturer are acceptable and can be used with
laboratories operating XE-2100s. This recommendation
stands for both the below-average and average analyz-
ers. The results of this work will be embraced by most
hematologists as they are usually less versed in statisti-
cal QC than their medical biochemistry colleagues. The
more demanding hematologist, can still use traditional
statistical limits. Based on Figures 2 and 3, the 14.5s
control rule would be adequate for most analytes and
the 13.5s control rule should sufﬁce for Hct.
It is probable that other hematology analyzers are
capable of such precise analytic performance. In order
for the hematology laboratory to totally embrace
expanded QC limits, manufacturers must make avail-
able their instruments’ usual imprecision’s as well as
well as their instruments’ poor imprecision’s (e.g. the
15P performance). Selection of control rules based on
average performance can be misleading; after all,
half the analyzers will deliver less than average
performance. Use of these expanded rules should
markedly reduce the needless re-analysis based on 13s
and 22s rule rejections and make the investigation of
outlyling QC observations far more rewarding. Users of
hematology analyzers who require the use of 13s and
22s to prevent the reporting of clinically erroneous data
are advised to replace their analyzers with more pre-
cise (and thus more dependable) instrumentation.
Figure 5. Difference between the maximum allowable error and quality control limits for 50th percentile analyzers
(level 2 control product).
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